Allergan plc and Medicines 360 today announced that LILETTA will be featured in 3 abstracts presenting new data at the FIGO World Congress of Gynecology and Obstetrics, which takes place from October 4-9, 2015 in Vancouver, Canada. The scheduled times and titles of the presentations are as follows: Presentation Date: Tuesday, October 6 th, Pre
Boston Therapeutics, Inc. today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd., completed enrollment for the clinical trial at The Chinese University of Hong Kong to evaluate BTI-320 in subjects who are pre-diabetic. This key developmental trial, being conducted in Hong Kong and the associated endpoints are pivotal for
Bristol-Myers Squibb will pay $14.6 million to settle charges from U.S. regulators that its joint venture in China gave cash and other benefits to government health care providers to boost drug sales. Bristol-Myers Squibb, based in New York, makes and sells prescription and over-the-counter medicines worldwide. Bristol-Myers Squibb was the lates
Flamel Technologies announced today that the Company's Irish subsidiary, Flamel Ireland Limited, has licensed exclusive U.S. rights to the LiquiTime drug delivery platform to Perrigo's Irish subsidiary, Elan Pharma International Limited, for the U.S. LiquiTime is Flamel's drug delivery platform for modified, extended and controlled release of
Release date- 02102015- Paris, France- Ipsen today announced that, in collaboration with the U.S. Ipsen markets the orphan drug, which is considered to be a drug of medical necessity, in the United States and most European countries. On 25 April 2013, Ipsen announced that the supplier of Increlex's active ingredient, Lonza Biologics Inc, was facing
DUBLIN and LOUISVILLE, Ky., Oct. 2, 2015/ PRNewswire/ Allergan plc, a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc., one of the nation's leading health and well-being companies, to explore new ideas and ways to improve the health and well-being of patients, members and their
Allergan, plc is pleased to announce that KYBELLA injection, the first and only FDA- approved injectable treatment for improving the appearance of moderate to severe submental fullness, also known as "double chin," received a "2015 Breakthrough Award" from Allure Magazine. The publication honored KYBELLA , along with other winners from their
For those on Medicare, this month can be critical. Those who ignore the open enrollment season, which runs Oct. 15 through Dec. 7, could wind up paying hundreds of dollars in unnecessary prescription drug charges next year, especially as some drug prices have soared in recent months, say Medicare experts. It's also a potentially treacherous period,
International Business Systems, a leading global integrated ERP and supply chain provider, today announced Sunset Pharmaceuticals, a primary wholesaler of pharmaceutical and medical supplies, has selected IBS Enterprise to support its business expansion in small-to-medium-size medical surgery markets. Sunset Pharmaceuticals is a rapidly growing..
Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel prescription products for the medical aesthetics market. Allergan acquired Kythera in an all-cash transaction.
Ipsen Biopharmaceuticals, an affiliate of Ipsen, today announced that in collaboration with the U.S. Food and Drug Administration an additional batch of Increlex will be available for commercial distribution starting in November 2015. "With the new resupply, additional Increlex will be available for children in the U.S. who depend on this
Ipsen today announced that, in collaboration with the U.S. Ipsen markets the orphan drug, which is considered to be a drug of medical necessity, in the United States and most European countries. On 25 April 2013, Ipsen announced that the supplier of Increlex s active ingredient, Lonza Biologics Inc, was facing manufacturing issues with Increl
Orexigen Therapeutics, Inc. today announced that Kwang Dong Pharmaceutical Company, Ltd., has filed a New Drug Application with the Ministry of Food and Drug Safety in South Korea for Contrave as a monotherapy for weight management in overweight or obese adult patients. Obesity and related comorbidities are a serious health problem in South Ko
SUMMARY: The Food and Drug Administration is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve
Allergan plc,, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. "As the leader in medical aesthetics, Allergan is committed to co
The first marketing activities are expected in 2017 and should cover key countries in Europe. The strategy of incremental innovation implemented by the Group in the OTC area combines the expertise acquired by Omega Pharma, a global company aimed at offering a wide range of high-quality therapeutic solutions to patients in North America, Europe and.
-Evofem, Inc. today announced that a New Drug Application for Amphora has been accepted for filing by the United States Food and Drug Administration. "We are delighted that the FDA has accepted this filing for Amphora," said Evofem CEO Saundra Pelletier. Evofem, Inc. is a privately held biotechnology company that discovers, develops and commercial
A unique international tool criminalizing the trade of counterfeit medicines, the Medicrime Convention, will enter into force on 1 st January 2016, after 5 countries out of its 24 signatories completed the ratification process. The Medicrime Convention, launched by the Council of Europe in December 2010 is opened for signature by all countries in t
Sheryl A. Kingsberg, PhD, Chief of Behavioral Medicine in the Department of OB/GYN at University Hospitals Case Medical Center in Cleveland, will present the findings during an oral presentation, "Women s Attitudes and Behaviors towards Vulvar and Vaginal Atrophy." This announcement was made by University Hospitals Case Medical Center and Therap